![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Implements Broad Label Change, Adding Warning for All Testosterone Products
FDA Implements Broad Label Change, Adding Warning for All Testosterone Products
![](https://www.fdanews.com/ext/resources/test/Drug-Images/Pharma-Labels.gif?t=1433873566&width=430)
October 26, 2016
The FDA is requiring a broad new warning to all labels for prescription testosterone products on the risks associated with abuse of anabolic androgenic steroids.
Prescription testosterone products are only approved by FDA as a hormone replacement therapy for men who have low testosterone due to certain medical conditions, genetic problems or damage to the testicles from chemotherapy or infection.
Upcoming Events
-
21Oct